» Articles » PMID: 30398622

An ITRAQ-Based Quantitative Proteomic Analysis of Plasma Proteins in Preterm Newborns With Retinopathy of Prematurity

Abstract

Purpose: Retinopathy of prematurity (ROP) is a vision-threatening complication of a premature birth, in which the etiology still remains unclear. Importantly, the molecular processes that govern these effects can be investigated in a perturbed plasma proteome composition. Thus, plasma proteomics may add new insights into a better understanding of the pathogenesis of this disease.

Methods: The cord and peripheral blood of neonates (≤30 weeks gestational age) was drawn at birth and at the 36th postmenstrual week (PMA), respectively. Blood samples were retrospectively subdivided into ROP(+) and ROP(-) groups, according to the development of ROP.

Results: The quantitative analysis of plasma proteome at both time points revealed 30 protein abundance changes between ROP(+) and ROP(-) groups. After standardization to gestational age, children who developed ROP were characterized by an increased C3 complement component and fibrinogen level at both analyzed time points.

Conclusions: Higher levels of the complement C3 component and fibrinogen, present in the cord blood and persistent to 36 PMA, may indicate a chronic low-grade systemic inflammation and hypercoagulable state that may play a role in the development of ROP.

Citing Articles

Host-derived protein profiles of human neonatal meconium across gestational ages.

Shitara Y, Konno R, Yoshihara M, Kashima K, Ito A, Mukai T Nat Commun. 2024; 15(1):5543.

PMID: 39019879 PMC: 11255260. DOI: 10.1038/s41467-024-49805-w.


4D label-free proteomics analysis of oxygen-induced retinopathy with or without anti-VEGF treatment.

Xu Z, Wu Y, Mao J, Chen Y, Chen H, Zhang S BMC Genomics. 2024; 25(1):415.

PMID: 38671350 PMC: 11046906. DOI: 10.1186/s12864-024-10340-z.


Cord blood transforming growth factor-β-induced as predictive biomarker of retinopathy of prematurity in preterm infants.

Song J, Woo S, Park K, Joo E, Kim H, Oh E Graefes Arch Clin Exp Ophthalmol. 2023; 261(9):2477-2488.

PMID: 37022494 DOI: 10.1007/s00417-023-06056-7.


LRG1 as a novel therapeutic target in eye disease.

De Rossi G, Da Vitoria Lobo M, Greenwood J, Moss S Eye (Lond). 2022; 36(2):328-340.

PMID: 34987199 PMC: 8807626. DOI: 10.1038/s41433-021-01807-4.


Plasma levels of amino acids and derivatives in retinopathy of prematurity.

Zhou Y, Xu Y, Zhang X, Huang Q, Tan W, Yang Y Int J Med Sci. 2021; 18(15):3581-3587.

PMID: 34522185 PMC: 8436098. DOI: 10.7150/ijms.63603.